This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CRANBURY, N.J., Jan. 10, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present the Company's full-year 2014 strategic outlook at the 32
nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 11:30 a.m. PT (2:30 p.m. ET).
A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.
About Amicus TherapeuticsAmicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones
migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and
AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.
CONTACT: Amicus Therapeutics